Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)

Ami V. Desai(University of Chicago Medical Center), Elizabeth Fox(Children's National), Ellen M. Basu(Memorial Sloan Kettering Cancer Center), Luke Maese(University of Utah), Amy E. Armstrong(Washington University in St. Louis), Amit J. Sabnis(University of California, San Francisco), Amar Gajjar(St. Jude Children's Research Hospital), Brian Weiss(Cincinnati Children's Hospital Medical Center), Janet Yoon(University of California San Diego), Karen Gauvain(Washington University in St. Louis), Mufiza Farid‐Kapadia(Roche (Canada)), Nicholas Whipple(University of Utah), Giles Robinson(St. Jude Children's Research Hospital), Clare Devlin(Roche (United Kingdom)), Alison K. Cardenas, Margaret E. Macy(Children's Hospital Colorado), Jennifer H. Foster(Children's Cancer Center), Thomas F. Cash(University of Liverpool), Suzanne Shusterman(Dana-Farber Cancer Institute), Christine A. Pratilas(Johns Hopkins University), Guillaume Bergthold(Roche (Switzerland)), Georgina Meneses‐Lorente(Roche (United Kingdom)), Saibah Chohan(Roche (Canada)), Lynley V. Marshall(Royal Marsden Hospital), Hubert Caron(Roche (Switzerland)), Mohamed S Abdelbaki(Nationwide Children's Hospital), Nadège Corradini(Institut d’Hématologie et d’Oncologie Pédiatrique), Katherine E. Hutchinson(Vanderbilt University), Edna Chow Maneval(Dana (United States))
Neuro-Oncology
April 8, 2022
Cited by 136


Related Papers